艾迪亚生物科技

US · IDYA #2357 按市值排名上市于 2019

32.85 -1.00 -2.95%

实时 - 追踪5344个代码 - 心跳于81秒前 · 2026-10-16 19:45

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了1家。
机构持股总比例下降了0.1个百分点。

机构持股

机构持股比例: 107.17% -0.11pp
机构数量: 342 -1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund79.21%

Hedge Fund19.82%

Public Company3.87%

VC/PE Fund2.41%

Individual/Insider0.88%

Government Pension Fund0.87%

Insurance Company0.49%

Private Company0.40%

主要股东截至 2026-06-30

FMR 14.62% · 14.10M 股

BlackRock 9.22% · 8.89M 股

Janus Henderson Group plc 8.89% · 8.58M 股

Capital Research 5.54% · 5.34M 股

Baker Bros. Advisors LP 5.19% · 5.01M 股

Vanguard Capital Management, LLC 4.93% · 4.75M 股

State Street Global Advisors 4.71% · 4.55M 股

Logos Global Management, L.P. 3.11% · 3.00M 股

Adage Capital Management, L.P. 2.81% · 2.72M 股

Deerfield Management Company, L.P. 2.81% · 2.71M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 43次买入 · 5次卖出

姓名	职务	持股比例
Yujiro Hata	Chief Executive Officer	0.72%
Jason Throne	Chief Legal Officer & Company Secretary	0.07%
Jeffrey Stein	Independent Director	0.06%
Andres Briseno	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	0.03%
Terry Rosen	Independent Chairperson	0.01%
Douglas Snyder	General Counsel	0.00%
Wendy Yarno	Independent Director	--
Scott William Morrison	Independent Director	--
Catherine Mackey	Independent Director	--
Darrin Beaupre	Chief Medical Officer	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-07-06	Andres Briseno	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	Derivative Exercise and Sale	-9,550	$12.86–40.01
2026-06-15	Wendy Yarno	Independent Director	Other Derivative Acquisition	+20,000	$30.57
2026-06-15	Jeffrey Stein	Independent Director	Other Derivative Acquisition	+20,000	$30.57
2026-06-15	Scott William Morrison	Independent Director	Other Derivative Acquisition	+20,000	$30.57
2026-06-15	Catherine Mackey	Independent Director	Other Derivative Acquisition	+20,000	$30.57
2026-06-15	Terry Rosen	Independent Chairperson	Other Derivative Acquisition	+20,000	$30.57
2026-06-15	Malcolm Hampton	Independent Director	Other Derivative Acquisition	+20,000	$30.57
2026-03-01	Jeffrey Stein	Independent Director	Open Market Acquisition	+50,000	$32.96
2026-01-29	Yujiro Hata	Chief Executive Officer	Other Derivative Acquisition	+600,000	$32.19
2026-01-29	Douglas Snyder	General Counsel	Other Derivative Acquisition	+130,000	$32.19
2026-01-29	Darrin Beaupre	Chief Medical Officer	Other Derivative Acquisition	+175,000	$32.19
2026-01-29	Andres Briseno	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	Other Derivative Acquisition	+80,000	$32.19
2026-01-29	Michael White	Chief Scientific Officer	Other Derivative Acquisition	+190,000	$32.19
2026-01-29	Stuart Dorman	Chief Commercial Officer	Other Derivative Acquisition	+155,000	$32.19
2026-01-29	Joshua Bleharski	Chief Financial Officer	Other Derivative Acquisition	+170,000	$32.19
2025-11-27	Douglas Snyder	General Counsel	Other Acquisition	+2,080	$16.91
2025-11-27	Andres Briseno	Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations	Other Acquisition	+1,935	$16.91–23.26
2025-06-26	Joshua Bleharski	Chief Financial Officer	Initial Statement of Beneficial	0	--
2025-06-23	Wendy Yarno	Independent Director	Other Derivative Acquisition	+20,000	$21.78
2025-06-23	Jeffrey Stein	Independent Director	Other Derivative Acquisition	+20,000	$21.78

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:45:45 · 仅供参考，不构成投资建议，也未考虑您的具体情况。